Pharmaceuticals News and Research

RSS

First study to show cost-effectiveness of pre-diabetes intervention

More than 40 million Americans face a high risk of developing Type 2 diabetes, and it would cost a lot to give all of them intensive help with diet and exercise, or medication, to keep them from developing diabetes.

28 Feb 2005

Scientists discover the origin of hydration force

Scientists at the Universitat Autònoma de Barcelona and Imperial College London have discovered the origin of hydration force, a phenomenon that causes some complex chemical and biochemical species (including DNA and other electrostatically charged molecules) to repel at short distances when surrounded by water.

28 Feb 2005

Project targeting the increasing resistance of some viruses to drugs

A new project targeting the increasing resistance of some viruses to drugs is being funded with the help of nine million euros under the Life Sciences, Genomics and Biotechnology for Health area of the EU’s Framework Programme.

28 Feb 2005

Cigarette smokers have an increased risk of experiencing rotator cuff tears

Cigarette smokers have an increased risk of experiencing rotator cuff tears in their shoulders than their tobacco-free counterparts, according to study results presented today at the 72nd Annual Meeting of the American Academy of Orthopaedic Surgeons.

27 Feb 2005

New compounds for the treatment of HIV/AIDS

Scientists from Tibotec Pharmaceuticals Ltd. presented data on several new compounds for the treatment of HIV/AIDS at the 12th Conference on Retroviruses and Opportunistic Infections (CROI), held February 22-25 in Boston, MA, USA.

27 Feb 2005

European approval of Pegasys for the treatment of chronic hepatitis B

The approval is granted for both types of the disease – HBeAg-positive and HBeAg-negative chronic hepatitis B. Pegasys offers the hope of a treatment-free life for thousands of people with chronic hepatitis B as this innovative drug has been shown to achieve lasting remission for a significant proportion of patients.

27 Feb 2005

Caution against FDA approval of race-based pharmaceutical

New York University Sociologist Troy Duster concludes that a pharmaceutical to combat heart disease among blacks is based on faulty research and urges the Food and Drug Administration to obtain more reliable data before approving the drug.

27 Feb 2005

Gel provides protection from HIV and herpes

Mount Sinai School of Medicine researchers demonstrated that a gel applied in the vagina provides protection from both the human immunodeficiency virus (HIV) and the herpes simplex Virus. The study, presented at the 12th Conference on Retroviruses and Opportunistic Infections, is the first to show that a gel can retain anti-viral activity within the human vagina.

27 Feb 2005

New imaging technology may serve as objective outcome measures for orthopedic conditions

New imaging technologies are enabling doctors to not only diagnose a variety of orthopaedic and musculoskeletal conditions with more accuracy, but also to determine with unprecedented precision whether clinical recovery from bone, joint or tendon damage is actually complete and not simply a "placebo effect."

27 Feb 2005

Americans believe drug industry cares more about profits than people

Americans believe prescription drugs are improving their lives, but most also say that the drug industry cares more about profits than people, according to the latest Kaiser Health Poll Report issued by the Kaiser Family Foundation.

27 Feb 2005

Second-generation Antidepressants

A recent article in the prestigious British Medical Journal seems to confirm an increased risk for suicidal behavior among adults taking popular antidepressants. This follows evidence that certain selective serotonin reuptake inhibitors (SSRIs) may have a similar effect among children and adolescents.

27 Feb 2005

Pfizer acquires Idun Pharmaceuticals

Pfizer today announced that it has entered into an agreement to acquire Idun Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of therapies to control apoptosis, a process of cell death that occurs in a broad range of diseases.

24 Feb 2005

$71 million to launch a new drug

Mid-level pharmaceutical brands invest an average of $71 million in marketing between Phase III trials and the first year on the market, according to a new report from Cutting Edge Information.

24 Feb 2005

Discovery could lead to the prevention, and possibly treatment of autoimmune diseases such as Type 1 diabetes

Scientists at the University of Maryland School of Medicine in Baltimore have identified a way to prevent Type I diabetes in rats that are genetically prone to develop the disease.

23 Feb 2005

Lack of early market research spending lowers drug success rates

Pharmaceutical market research spending during Launch exceeds all market research spending from Pre-Clinical to Phase III, according to a new industry report by Cutting Edge Information. This lack of early market research spending dramatically reduces a product's viability in the competitive marketplace.

23 Feb 2005

Feverfew or Bachelor's Button, kills human leukemia stem cells like no other single therapy

A daisy-like plant known as Feverfew or Bachelor's Button, a traditional remedy for reducing fevers and a treatment for nervousness, hysteria and low spirits, is the source of an agent that kills human leukemia stem cells like no other single therapy

23 Feb 2005

FDA approval of Vaccinia Immune Globulin to treat adverse reactions to smallpox vaccination

Computer Sciences Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved its Vaccinia Immune Globulin (VIGIV), an intravenous immune globulin, to treat rare adverse reactions to smallpox vaccination.

22 Feb 2005

State-of-the-art computer technology to tackle deadly diseases such as influenza

Researchers at the University of Bath have won a £261,000 grant to use the latest software to produce a blueprint of a designer drug that could stop influenza and some other diseases from replicating in humans.

22 Feb 2005

Pharmaceutical and biotechnology industry in the new EU countries presents considerable potential

In contrast to subdued growth in the pharmaceutical markets of the former 15-state European Union (EU), pharmaceutical markets in the 'new' EU accession markets are expanding vibrantly.

22 Feb 2005

Pharmaceutical companies will be named and shamed for misleading advertising

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) will be naming and shaming companies which engage in misleading advertising of their pharmaceutical products, or which show poor practice in the way they set about their advertising and promotional campaigns.

22 Feb 2005